多发性骨髓瘤的嵌合抗原受体T细胞疗法
多发性骨髓瘤(MM)几乎不可治愈,需要新疗法。CAR-T以不同于标准化疗的机制靶向抗原,靶向B细胞成熟抗原的CAR-T在早期临床试验中显示显著抗骨髓瘤活性,毒性包括细胞因子释放综合征,与白血病CAR-T试验相似。
要点
- 靶向B细胞成熟抗原的CAR-T在早期临床试验中显示显著抗骨髓瘤活性。
- 毒性包括细胞因子释放综合征,与白血病CAR-T试验中观察到的毒性相似。
- MM遗传和表型异质性,可能常需靶向>1种抗原才能有效治疗。
核心结论
- MM几乎总是不可治愈的血浆细胞恶性肿瘤,需要新的治疗方法。
- CAR-T疗法治疗MM处于早期开发阶段,但有很大希望改善MM治疗。
- 将CAR-T与其他骨髓瘤疗法整合是未来研究的重要领域。
研究设计与样本
- 综述类文章,检索范围原文未报告。
主要发现
- 靶向B细胞成熟抗原的CAR-T在早期临床试验中显示显著抗骨髓瘤活性。
- 这些试验中的毒性包括细胞因子释放综合征,与白血病CAR-T试验中观察到的毒性相似。
- 用抗CD19 CAR-T靶向推测的CD19+骨髓瘤干细胞是MM治疗的一种新方法。
- CD138、CD38、信号淋巴细胞激活分子7和κ轻链等MM抗原正在作为CAR靶点研究。
- MM具有遗传和表型异质性,因此用CAR-T有效治疗MM可能常需要靶向>1种抗原。
关键数值与推荐
- CAR的靶抗原必须在恶性细胞上表达,但在正常细胞上的表达必须缺失或有限。
- B细胞成熟抗原由正常和恶性浆细胞表达。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multiple myeloma (MM) is a nearly always incurable malignancy of plasma cells, so new approaches to treatment are needed. T-cell therapies are a promising approach for treating MM, with a mechanism of action different than those of standard MM treatments. Chimeric antigen receptors (CARs) are fusion proteins incorporating antigen-recognition domains and T-cell signaling domains. T cells genetically engineered to express CARs can specifically recognize antigens. Success of CAR-T cells (CAR-Ts) against leukemia and lymphoma has encouraged development of CAR-T therapies for MM. Target antigens for CARs must be expressed on malignant cells, but expression on normal cells must be absent or limited. B-cell maturation antigen is expressed by normal and malignant plasma cells. CAR-Ts targeting B-cell maturation antigen have demonstrated significant antimyeloma activity in early clinical trials. Toxicities in these trials, including cytokine release syndrome, have been similar to toxicities observed in CAR-T trials for leukemia. Targeting postulated CD19+ myeloma stem cells with anti-CD19 CAR-Ts is a novel approach to MM therapy. MM antigens including CD138, CD38, signaling lymphocyte-activating molecule 7, and κ light chain are under investigation as CAR targets. MM is genetically and phenotypically heterogeneous, so targeting of >1 antigen might often be required for effective treatment of MM with CAR-Ts. Integration of CAR-Ts with other myeloma therapies is an important area of future research. CAR-T therapies for MM are at an early stage of development but have great promise to improve MM treatment.
引用
- Mikkilineni L, Kochenderfer JN. Chimeric antigen receptor T-cell therapies for multiple myeloma. Blood. 2017. PMID: 28928126. doi:10.1182/blood-2017-06-793869
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。